The short-term effects of Conbercept intravitreal injection on matrix metalloproteinase-2 and tissue inhibitor of metalloproteinases-2 expression in the aqueous humor of eyes with proliferative diabetic retinopathy_Chinese Journal of Ocular Fundus Diseases

Authors：

Zhang Wei , Zhu Kai , Jia Wen , Zhang Rui , Li Xuran ,  Gu Yonghao

Department of Ophthalmology, The First Affiliated Hospital of University of Science and Technology, Anhui Province Hospital, Hefei 230001, China;

Corresponding author：

Gu Yonghao, Email: guyh@ustc.edu.cn

Keywords：

Diabetic retinopathy; Vascular endothelial growth factor; Matrix metalloproteinase; Tissue inhibitor of metalloproteinase; Conbercept

DOI：

10.3760/cma.j.cn511434-20240902-00328

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To observe and analyze the short-term effects of intravitreal injection of Conbercept (IVC) on the expression levels of matrix metalloproteinase (MMP)-2 and MMP inhibitor-2 (TIMP-2) in the aqueous humor of eyes with proliferative diabetic retinopathy (PDR). Methods A prospective clinical study. From March 2024 to June 2024, 30 consecutive patients with 30 eyes with PDR (PDR group) undergoing IVC combined with pars plana vitrectomy (PPV) at Department of Ophthalmology of The First Affiliated Hospital of University of Science and Technology were included in the study, along with 20 patients with 20 eyes undergoing cataract surgery (control group) during the same period. In the PDR group, IVC treatment was performed 3 to 7 days before PPV, and 0.05-0.10 ml aqueous humor was collected before IVC and before PPV. In the control group, 0.05-0.10 ml aqueous humor was collected before cataract surgery. The levels of vascular endothelial growth factor (VEGF), MMP-2, and TIMP-2 in the aqueous humor were measured using enzyme-linked immunosorbent assay. For normally distributed data, independent samples t-test were used for comparison between two groups; for non-normally distributed data, the Mann-Whitney U test was used. The correlation analysis of VEGF, MMP-2, TIMP-2 concentrations in aqueous humor of PDR patients was performed using Pearson's correlation coefficient. Results There were no statistically significant differences in age (Z=－1.810) and gender composition (χ²=3.450) between the PDR group and the control group (P＞0.05). Before IVC, VEGF and MMP-2 expression levels were (0.23±0.10), (2.11±1.32) ng/ml and (0.12±0.03), (0.53±0.26) ng/ml in patients' aqueous fluid in PDR group and control group, respectively. The expression level of TIMP-2 and the ratio of MMP-2/TIMP-2 were (0.99±0.26), (1.76±0.11) ng/ml and 2.04 (1.19, 2.98), 0.36 (0.15, 0.39), respectively. Compared with the control group, the expression levels of VEGF and MMP-2 in aqueous humor in PDR group (t=－5.030, －5.260) and the ratio of MMP-2/TIMP-2 (Z=－5.740) were significantly increased, with statistical significance (P＜0.01). The expression level of TIMP-2 was significantly lower than that of control group, the difference was statistically significant (t=12.120, P＜0.01). After IVC, the expression levels of VEGF and MMP-2 in aqueous humor of PDR patients were (0.13±0.03) and (2.11±1.32) ng/ml, respectively. The expression level of TIMP-2 and the ratio of MMP-2/TIMP-2 were (0.95±0.28) ng/ml and 1.57 (1.02, 3.13), respectively. Compared with before IVC, the expression level of VEGF in aqueous humor in PDR group after IVC was significantly decreased, and the difference was statistically significant (t=6.080, P＜0.01). The expression levels of MMP-2 (t=1.220), TIMP-2 (t=0.290) and the ratio of MMP-2/TIMP-2 (Z=－0.260) were not significantly different (P=0.270, 0.780, 0.800). After IVC, there was no significant difference in VEGF expression level between PDR group and control group (t=－1.200, P=0.240). The expression level of MMP-2 was still significantly increased (t=－5.880), the expression level of TIMP-2 was still significantly decreased (t=11.520), and the ratio of MMP-2/TIMP-2 was still significantly increased (Z=－5.780), with statistical significance (P＜0.01). Correlation analysis showed that VEGF was positively correlated with MMP-2 in aqueous humor of PDR patients before IVC (r=0.590, P＜0.01). Conclusions IVC can effectively reduce the level of VEGF in the aqueous humor of eyes with PDR in the short term, but it has no significant effect on the levels of MMP-2 and TIMP-2.

Citation： Zhang Wei, Zhu Kai, Jia Wen, Zhang Rui, Li Xuran, Gu Yonghao. The short-term effects of Conbercept intravitreal injection on matrix metalloproteinase-2 and tissue inhibitor of metalloproteinases-2 expression in the aqueous humor of eyes with proliferative diabetic retinopathy. Chinese Journal of Ocular Fundus Diseases, 2025, 41(1): 7-14. doi: 10.3760/cma.j.cn511434-20240902-00328 Copy

1.
2.	Yue T, Shi Y, Luo S, et al. The role of inflammation in immune system of diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications[J/OL]. Front Immunol, 2022, 13: 1055087[2022-12-13]. https://pubmed.ncbi.nlm.nih.gov/36582230/. DOI: 10.3389/fimmu.2022.1055087.
3.
4.	Caban M, Owczarek K, Lewandowska U. The role of metalloproteinases and their tissue inhibitors on ocular diseases: focusing on potential mechanisms[J/OL]. Int J Mol Sci, 2022, 23(8): 4256[2022-04-12]. https://pubmed.ncbi.nlm.nih.gov/35457074/. DOI: 10.3390/ijms23084256.
5.	Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, et al. The roles of matrix metalloproteinases and their inhibitors in human diseases[J/OL]. Int J Mol Sci, 2020, 21(24): 9739[2020-12-20]. https://pubmed.ncbi.nlm.nih.gov/33419373/. DOI: 10.3390/ijms21249739.
6.
7.
8.
9.
10.	Wang Q, Li T, Wu Z, et al. Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo[J/OL]. PLoS One, 2013, 8(8): e70544[2013-08-12]. https://pubmed.ncbi.nlm.nih.gov/23950958/. DOI: 10.1371/journal.pone.0070544.
11.
12.
13.	Wang W, Qu C, Yan H. Network meta-analysis of intravitreal conbercept as an adjuvant to vitrectomy for proliferative diabetic retinopathy[J/OL]. Front Endocrinol (Lausanne), 2023, 14: 1098165[2023-02-22]. https://pubmed.ncbi.nlm.nih.gov/36896181/. DOI: 10.3389/fendo.2023.1098165.
14.	Yang Z, Di Y, Ye J, et al. Comparison of the adjuvant effect of conbercept intravitreal injection at different times before vitrectomy for proliferative diabetic retinopathy[J/OL]. Front Endocrinol (Lausanne), 2023, 14: 1171628[2023-05-26]. https://pubmed.ncbi.nlm.nih.gov/37305048/. DOI: 10.3389/fendo.2023.1171628.
15.
16.
17.
18.
19.
20.
21.	Lehmann GL, Ginsberg M, Nolan DJ, et al. Retinal pigment epithelium-secreted VEGF-A induces alpha-2-macroglobulin expression in endothelial cells[J/OL]. Cells, 2022, 11(19): 2975[2022-09-24]. https://pubmed.ncbi.nlm.nih.gov/36230937/. DOI: 10.3390/cells11192975.
22.
23.
24.
25.
26.	Shen Y, Gu J, Liu Z, et al. Inhibition of HIF-1α reduced blood brain barrier damage by regulating MMP-2 and VEGF during acute cerebral ischemia[J/OL]. Front Cell Neurosci, 2018, 12: 288[2018-09-04]. https://pubmed.ncbi.nlm.nih.gov/30233326/. DOI: 10.3389/fncel.2018.00288.
27.
28.	Song S, Yu X, Zhang P, et al. Increased levels of cytokines in the aqueous humor correlate with the severity of diabetic retinopathy[J/OL]. J Diabetes Complications, 2020, 34(9): 107641[2020-05-30]. https://pubmed.ncbi.nlm.nih.gov/32605862/. DOI: 10.1016/j.jdiacomp.2020.107641.
29.
30.	刘东宁. 基质金属蛋白酶在增殖性糖尿病视网膜病变增殖膜中的表达研究[D]. 沈阳: 中国医科大学, 2004.Liu DL. Study on the expression of matrix metalloproteinases in proliferative membranes of proliferative diabetic retinopathy[D]. Shenyang: China Medical University, 2004.

1.
2. Yue T, Shi Y, Luo S, et al. The role of inflammation in immune system of diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications[J/OL]. Front Immunol, 2022, 13: 1055087[2022-12-13]. https://pubmed.ncbi.nlm.nih.gov/36582230/. DOI: 10.3389/fimmu.2022.1055087.
3.
4. Caban M, Owczarek K, Lewandowska U. The role of metalloproteinases and their tissue inhibitors on ocular diseases: focusing on potential mechanisms[J/OL]. Int J Mol Sci, 2022, 23(8): 4256[2022-04-12]. https://pubmed.ncbi.nlm.nih.gov/35457074/. DOI: 10.3390/ijms23084256.
5. Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, et al. The roles of matrix metalloproteinases and their inhibitors in human diseases[J/OL]. Int J Mol Sci, 2020, 21(24): 9739[2020-12-20]. https://pubmed.ncbi.nlm.nih.gov/33419373/. DOI: 10.3390/ijms21249739.
6.
7.
8.
9.
10. Wang Q, Li T, Wu Z, et al. Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo[J/OL]. PLoS One, 2013, 8(8): e70544[2013-08-12]. https://pubmed.ncbi.nlm.nih.gov/23950958/. DOI: 10.1371/journal.pone.0070544.
11.
12.
13. Wang W, Qu C, Yan H. Network meta-analysis of intravitreal conbercept as an adjuvant to vitrectomy for proliferative diabetic retinopathy[J/OL]. Front Endocrinol (Lausanne), 2023, 14: 1098165[2023-02-22]. https://pubmed.ncbi.nlm.nih.gov/36896181/. DOI: 10.3389/fendo.2023.1098165.
14. Yang Z, Di Y, Ye J, et al. Comparison of the adjuvant effect of conbercept intravitreal injection at different times before vitrectomy for proliferative diabetic retinopathy[J/OL]. Front Endocrinol (Lausanne), 2023, 14: 1171628[2023-05-26]. https://pubmed.ncbi.nlm.nih.gov/37305048/. DOI: 10.3389/fendo.2023.1171628.
15.
16.
17.
18.
19.
20.
21. Lehmann GL, Ginsberg M, Nolan DJ, et al. Retinal pigment epithelium-secreted VEGF-A induces alpha-2-macroglobulin expression in endothelial cells[J/OL]. Cells, 2022, 11(19): 2975[2022-09-24]. https://pubmed.ncbi.nlm.nih.gov/36230937/. DOI: 10.3390/cells11192975.
22.
23.
24.
25.
26. Shen Y, Gu J, Liu Z, et al. Inhibition of HIF-1α reduced blood brain barrier damage by regulating MMP-2 and VEGF during acute cerebral ischemia[J/OL]. Front Cell Neurosci, 2018, 12: 288[2018-09-04]. https://pubmed.ncbi.nlm.nih.gov/30233326/. DOI: 10.3389/fncel.2018.00288.
27.
28. Song S, Yu X, Zhang P, et al. Increased levels of cytokines in the aqueous humor correlate with the severity of diabetic retinopathy[J/OL]. J Diabetes Complications, 2020, 34(9): 107641[2020-05-30]. https://pubmed.ncbi.nlm.nih.gov/32605862/. DOI: 10.1016/j.jdiacomp.2020.107641.
29.
30. 刘东宁. 基质金属蛋白酶在增殖性糖尿病视网膜病变增殖膜中的表达研究[D]. 沈阳: 中国医科大学, 2004.Liu DL. Study on the expression of matrix metalloproteinases in proliferative membranes of proliferative diabetic retinopathy[D]. Shenyang: China Medical University, 2004.

Chinese Journal of Ocular Fundus Diseases

The short-term effects of Conbercept intravitreal injection on matrix metalloproteinase-2 and tissue inhibitor of metalloproteinases-2 expression in the aqueous humor of eyes with proliferative diabetic retinopathy

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content